What triggers kidney cancer cells to metastasise?

Researchers at the University of California in San Diego, USA, have discovered how the environment surrounding a tumour can trigger the cancer cells to spread (metastasise). The researchers have published their findings in the journal, Nature Communications. The researchers found that when tumour cells are confined in a dense environment, a specific set of genes, called […]

read more

Adjuvant therapy for high risk kidney cancer

Dr Umberto Capitanio from the Department of Urology, San Raffaele Scientific Institute, Milan, Italy, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases. In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to […]

read more

The impact of immunotherapy on the treatment of kidney cancer

Professor Thomas Powles, Barts Cancer Institute, London discusses the impact of immunotherapy on the treatment of kidney cancer. There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles. CheckMate-214 is the study credited with potentially changing the frontline treatment of this […]

read more

Majority of people in the UK do not know that obesity can increase the risk of some cancers

A new study from Cancer Research UK and published in the Journal of Public Health surveyed 3293 adults, representative of the UK population. The results from this study showed that the majority of people in the UK do not understand the connection between weight issues and cancer. Obesity is associated with thirteen types of cancer, including breast, […]

read more

Risk factors for bone metastases from renal cell carcinoma

Data from 372 people with renal cell carcinoma (RCC) were used in a retrospective study to look at the risk factors for the development of bone metastases. Of the 372 people investigated, 38 developed bone metastases. Analysis of blood samples showed that high levels of a protein called alkaline phosphatase, high levels of calcium and […]

read more

Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer

The US Food and Drug Administration (FDA) has approved sunitinib (Sutent) for adjuvant treatment of adults who have had their kidney cancer removed, but who are at high risk of the cancer returning. Sunitinib is a tyrosine kinase inhibitor (TKI) that works by blocking several enzymes that promote cell growth and the formation of new […]

read more

Joint working project between the Royal Marsden and Novartis to improve cancer services

A new joint working project between Novartis and the Royal Marsden Partners Cancer Vanguard is being piloted in North West and South West London. The project aims to improve quality of care in the region by expanding the role of oncology pharmacists to address increasing demand on oncology services. The project will develop and introduce […]

read more

Kidney cancer vaccine shows promise in early clinical trial

Results from a phase I clinical trial of a vaccine for renal cell carcinoma (RCC) were presented at the International Kidney Cancer Symposium in Miami last week by researchers from the University of California in Los Angeles, USA. In the study, three patients were given the highest dose of the vaccine. Two have exhibited stable […]

read more

Nivolumab improves survival of kidney cancer patients at three years

Updated results from the phase 3 CheckMate-025 study, presented at the 16th International Kidney Cancer Symposium in Miami, USA last week, show a three-year survival benefit of nivolumab (Opdivo) over everolimus (Afinitor) in advanced renal cell carcinoma (RCC). The risk of death was also reduced by 26% for the people taking nivolumab. CheckMate-025 evaluated previously […]

read more

Tivozanib plus nivolumab combination shows promise

AVEO Oncology and EUSA Pharma have announced promising results from the phase 1 portion of the TiNivo study, a phase 1/2 multicentre trial of tivozanib (Fotiva®) in combination with nivolumab (Opdivo®), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced renal cell carcinoma (RCC). The results were presented at the 16th International Kidney Cancer Symposium […]

read more
Showing 1 to 10 of 197 results
  TOP